Canadian biotech Medicago has the data it was hoping for from a phase 2 trial of its COVID-19 vaccine, partnered with GlaxoSmithKline, and is now hoping to have phase 3 data available "by early ...

Medicago said it would file the adjuvanted plant-based coronavirus vaccine for regulatory approval with Health Canada, the FDA and others.

Medicago plant-based vaccine imitates covid-19 spike protein. This latest candidate in the fight against covid-19 works similar to the other vaccines currently available triggering an immune ...

Canadian drug developer Medicago's plant-based COVID-19 vaccine candidate, enhanced by GlaxoSmithKline's booster, was 75.3% effective against the Delta variant of the virus in a late stage study ...

Medicago announced Tuesday that its two-dose vaccine was 71% effective at preventing COVID-19 infection in a large, late-stage study that included several variants including the delta variant.

Biotechnology company Medicago now has a facility that needs just 30 days to turn into new flu vaccine the plant that has been the cornerstone of North Carolina’s economy for hundreds of years. ...

Medicago – a Canadian company with a biomanufacturing facility in Durham – has used it to produce an experimental plant-based vaccine for COVID-19, the coronavirus disease that has now reached ...

Canadian vaccine maker Medicago's COVID-19 vaccine, approved last month in Canada, ... may still want Medicago's shot because of its plant-based technology, ...

Canada's Medicago, a biotech that is using plant technology to manufacture vaccines against Ebola and other viruses, will build a $200 million manufacturing facility in Quebec City. The company is ...

VLP vaccine will be produced using plant leaf production system. Canadian vaccines firm Medicago has been awarded $946,000 in funding from PATH as part of a research collaboration between the ...

Pharmaceutical companies Medicago and GlaxoSmithKline announced Tuesday “positive efficacy and safety results” from a global trial using what they say is the world’s first plant-based ...

Medicago announced Tuesday that its two-dose vaccine was 71% effective at preventing COVID-19 infection in a large, late-stage study that included several variants including the delta variant.